

# INVITATION

## 24 October 2024

# COSTEM 2024: THERAKOS MEET THE EXPERT SESSION

Virtual / Hotel nhow Berlin, Germany

This information is intended for healthcare professionals based in Europe and the Middle East.

## Agenda

**Time: 18:00 – 18:30 CET**

- 
- |               |   |
|---------------|---|
| 18:00 – 18:15 | <b>ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD</b><br><b>Prof. Nikolaus Kröger</b> , University Medical Center Hamburg-Eppendorf, Germany                               |
| 18:15 – 18:20 | <b>Q&amp;A</b>  |
| 18:20 – 18:30 | <b>Announcement of the winner of the Mallinckrodt 2024 Advancing ECP Immunomodulation Investigator Award: 30 Years of ECP in Graft versus Host Disease. Refining THERAKOS ECP Immunomodulation™</b> |

*ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease*

*Speaker subject to contract.*

***This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.***

[Privacy policy](#)

Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2024 Mallinckrodt. EU-2400070 March 2024.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.*